Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell

This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the 12-month visit with a TT switch within 6 months.

Some background

RA is a chronic, inflammatory disease for which several drug management options are available. Switching between available drugs is sometimes necessary to achieve remission/LDA targets.

First-line therapy is usually methotrexate (MTX; Otrexup), a conventional, synthetic disease-modifying anti-rheumatic drug (csDMARD). The addition of a biological DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARD) to first-line therapy is sometimes needed to achieve treatment targets. If the remission or LDA is not met by 6 months, then therapy adjustment with an alternative bDMARD or tsDMARD, is considered.

This study addresses whether a treat-to-target (T2T) strategy with a TT switch within the first 6 months, can allow target treatments to be met at the 12-month visit.

Methods & findings

This study included a total of 1275 patients with RA. Group 1 had 62 patients who had switched bDMARD/tsDMARD therapy within 6 months. Group 2 included 598 patients that did not require a 6-month therapy switch. Group 3 included 124 patients that did not respond to treatment within 6 months (followed a T2T strategy). Group 4 had 491 patients who were unresponsive to treatment within 6 months (did not follow a T2T strategy). The follow-up period was at least 1 year.

At 12 months, the highest improvement in the disease activity score-28 (DAS-28) was seen in group 2 (78.6%), followed by group 1 (48.4%), group 3 (40.3%), and group 4 (32.4%).

Patients that followed a T2T strategy from group 3 were 2.8 times more likely to achieve remission/LDA at the 12-month visit compared to those in group 4 who did not follow a T2T strategy.

The bottom line

The study showed that for patients with RA unable to achieve target goals within the first 6 months of treatment, a bDMARD/tsDMARD switch increases the chance of attaining remission/LDA at the 12-month visit.

The fine print

The study was not randomized and focused on first-line bDMARD, tsDMARD therapy.

Published By :

Arthritis Research & Therapy

Date :

Jan 06, 2021

Original Title :

Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry.

click here to get personalized updates